Register or Sign in to Save this opportunity, or Send an Inquiry.
Early Stage, CIS Pharma Develops Cellophil® Antibody Drug Conjugates (ADCs) to Upgrade the Arsenal Against Cancer.
CIS Pharma AG, Switzerland Switzerland flag Switzerland
Abstract ID:
CIS Pharma develops Cellophil® Antibody drug conjugates to conquer the limitations of conventional ADCs by increase of cytotoxic payloads even for strong hydrophobic drugs.
Send an Inquiry
Last Updated Feb 2019
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833